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التكلفة العالجية للربو يف عمان
نا�رسحمد البو�شعيدي ذو الفقار حبيب اهلل . جوان �شوريانو
التكلفة مبني على  و ح�شاب  الربو  انت�شار  الطريقة: مدى  ال�شلطنة.  الربو يف  لعالج  املبا�رسة  التكلفة  تقّيم  الدرا�شة  الهدف: هذه  امللخ�ص: 
نتائج عن جمموعة من اخلرباء با�شتخدام تقنية "دلفي". هذه احل�شابات مت تتطبيقها على جمموع �شكان عمان فوق عمر خم�ض �شنوات 
للح�شول على عدد امل�شابني بالربو يف عمان ومن ثم اخذ العدد املح�شوب من تقنية "دلفي" و�رسبه بن�شبة املر�شى الذين ي�شتخدمون 
امل�شت�شفيات احلكومية وذلك لتقدير عدد مر�شى الربو العمانيني املعاجلني يف عمان. التكلفة العالجية مت ح�شابها با�شتخدام العدد الناجت 
من من تقنية" دلفي" و الدرا�شات ال�شابقة ملر�ض الربو يف عمان بعنوان نظره اإىل واقع الربو يف منطقة اخلليج وال�رسق الأدنى. وح�شبت 
بالريال العماين والدولر الأمريكي. النتائج مدى انت�شار الربو يف عمان هو %7.3 يف الكبار و%12.7 يف الأطفال و هذا ميثل 96,470 
اأن  الدرا�شة  ال�شحية و امل�شت�شفيات احلكوميه. كذلك بينت  %95منهم يرتددون على املراكز  الأطفال.  الكبارو58,344 من  مر�شى من 
للعيادات   20% الطوارئ،  ق�شم  لزيارات   25% احلادة،  الربو  نوبات  ب�شبب  املنومني  للمر�شى  تعود  للربو  العالجية  التكلفة  من   55%
34,273,696 ريال  %0.2 من التكلفة العالجية لالأدوية. التكلفة الإجمالية بدون الأدوية  اخلارجية و جزء �شئيل جداً ميثل اقل من 
عماين 89,111,609( دولر اأمريكي( و27,014,735 ريال عماين 70,238,311( دولر اأمريكي( لالأطفال. و اإذا ما اأ�شفنا الأدوية 
امل�شتخدمة تقّدر التكلفة الإجمالية لعالج الربو يف عمان ما يزيد عن  61,500,294 ريال عماين 159,900,761( دولر اأمريكي(. 
اخلال�صة: بينت هذه الدرا�شة اأن التكلفة العالية لعالج الربو تعود اإىل الزيارات للطوارئ و للمر�شى املنومني ب�شبب حالت الربو احلادة 
مقارنه بالإنفاق الب�شيط لالأدوية، و لذا على املهتمني بهذا اجلانب النظر يف كيفية ال�شيطرة على اأعرا�ض الربو كاأولوية و لي�ض القت�شاد 
يف �رسف املبالغ اخلا�شة باأدوية الربو.
مفتاح الكلمات: ربو؛ تكلفه الربو؛ اأدويه الربو؛ اقت�شاد؛ ا�شتخدام اخلدمات ال�شحية؛ عمان.
abstract: Objectives: This study evaluates the direct costs of treating asthma in Oman. Methods: Asthma 
prevalence and unit cost estimates were based on results from a panel using the Delphi technique, and were applied 
to the total Omani population aged 5 and older to obtain the number of people diagnosed with asthma. The estimates 
from the Delphi exercise were multiplied by the percentage of patients using government facilities to estimate the 
number of asthma patients managed in Oman. Treatment costs were also calculated using data from the Delphi 
exercise and the Asthma Insights and Reality for the Gulf and Near East study (reported in Omani riyals [OMR] and 
US dollars [USD]). Results: The prevalence of asthma was estimated to be 7.3% of adults (n = 96,470) and 12.7% of 
children (n = 58,344). Of these, 95% of both adults and children were estimated to be using government healthcare 
facilities. Inpatient visits accounted for the largest proportion of total direct costs (55%), followed by emergency 
room and outpatient visits (25% and 20%, respectively) and medications (<0.2%). The annual cost of treatment 
excluding medications, was OMR 34,273,696 (USD 89,111,609) for adults and OMR 27,014,735 (USD 70,238,311) 
for children. Including medications, the total annual direct cost of asthma treatment was estimated to be over OMR 
61,500,294 (USD 159,900,761). Conclusion: Given the high medical expenditures associated with facility visits 
relative to the lower medication costs, the focus of Oman’s asthma cost savings should be on improving asthma 
control rather than reducing medication costs.
Keywords: Asthma; Cost of asthma; Asthma medications; Economy; Health service utilization; Oman.
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Advances in Knowledge
- This is the first study to address the cost of asthma in Oman.
- This study presents comprehensive Omani medical data.
Applications to Patient Care
- Proper outpatient management will reduce the cost of inpatient and emergency visits.
- Adequate management of asthma with proper medications will reduce the number of exacerbations and subsequent emergency room 
and inpatient visits.
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The World Health Organization (WHO) estimates that 300 million people suffer from asthma worldwide; it is the 
most common chronic illness among children, and 
one of the most frequent in adults.1 In the Phase 
III International Study of Asthma and Allergies in 
Children (ISAAC), 13.8% of school children aged 
13–14 years worldwide reported that they had had 
asthma at some time in their lives, although with 
large regional variability.2 
Given the prevalence of the disease and 
its symptoms, asthma imposes a considerable 
economic burden on healthcare systems. One study 
found that the annual direct medical expenditure 
for asthma treatment in the USA in 2007 was US 
dollars (USD) 37.2 billion.3 In Europe, the annual 
direct cost of asthma is estimated to be Euros (EUR) 
7.9 billion.4 Furthermore, another study in the USA 
found that the total incremental cost of asthma to 
society, also including indirect costs, was USD 56 
billion in 2007.5 
Estimation of national expenditure for asthma 
treatment can provide useful information to guide 
clinicians and policymakers in improving the 
management of asthma through better treatment. 
To our knowledge, medical literature is lacking in 
studies that estimate the costs of asthma treatment 
in Oman, although Bazdawi et al. reported the 
prevalence rates of reported diagnoses of asthma 
in older children (13–14 years old) at 20.7%, and 
at 10.5% in younger children in Oman (6–7 years 
old).6 Al Rawas and colleagues reported that 
asthma prevalence was increasing. The geographic 
variation in the prevalence of self-reported of 
asthma symptoms among Omani school children 
still persisted with further increase in the Sharqiya 
region. The findings also suggest under-diagnosis 
and/or poor recognition of asthma, which had not 
improved over time.7 The current study aims to 
evaluate the direct costs of treating asthma in Oman, 
specifically focusing on Omani nationals treated in 
government healthcare facilities in Oman. These 
include costs of outpatient treatment, hospital 
emergency visits, inpatient treatment, medicines, 
and total direct costs of treatment for asthma. 
Methods
Population figures were obtained from the 
2009 census data from the Omani Ministry of 
Economy.8 Drug usage and costs were provided 
by the Ministry of Healths (MOH) Purchasing 
Department.9 Typical treatment profiles, including 
emergency visits, outpatient visits, inpatient stays, 
and pharmacological treatment use were obtained 
from the Asthma Insights and Reality for the Gulf 
and Near East (AIRGNE) study.10 
Due to a lack of published data on asthma 
prevalence and unit costs of asthma treatment, 
a modified Delphi technique was used to gather 
consensus estimates of this data. One of the main 
advantages of using the Delphi technique rather 
than a face-to-face group panel approach is its 
ability to obtain expert knowledge from each 
participant without the influence of others involved 
in the study.11–13 The Delphi panel methodology 
consisted of consensus consultations with 10 
leading physicians in asthma treatment in Oman. 
Two rounds of data collection from the panel were 
conducted to determine these estimates.
Currently available data on asthma prevalence 
and unit costs of asthma treatment were provided 
to each of the panel members. Treatment costs 
included outpatient and emergency room (ER) 
visits, and inpatient costs for both adults and 
children. Each panel member provided their own 
expert estimates individually, including upper and 
lower estimates, in addition to a “best” estimate. An 
average of the combined estimates from the panel 
members in round one was calculated for each data 
input, and then used in round two. 
During round two, the panellists were given 
these mean values to consider, and were given the 
opportunity to revise their round one estimates 
where they thought it was appropriate. The revised 
estimates for prevalence and costs (for both adults 
and children) generated in this second round were 
used in the main calculations of the current study. 
Costs are reported in Omani riyals (OMR) and 
USD, using the 2010 exchange rate of 1 OMR = 
2.60010 USD.
The asthma prevalence determined in round 
two of the Delphi exercise was applied to the total 
Omani population aged 5 and over to obtain the 
percentage of individuals (both adults and children) 
diagnosed with asthma in Oman. Individuals aged 5 
to 15 were categorised as children, and those aged 
16 or older were categorised as adults. Estimates 
from round two were then multiplied by the 
percentage of patients using government facilities 
The Asthma Cost in Oman
220 | SQU Medical Journal, May 2013, Volume 13, Issue 2
as reported in the AIRGNE study to determine 
the total number of asthma patients managed in 
government healthcare facilities.10 
To obtain an estimation of total outpatient 
treatment costs, the total number of asthma 
patients treated in government healthcare facilities 
was multiplied by the average number of outpatient 
visits per year as reported in the AIRGNE study to 
determine the total number of outpatient visits per 
year which was then multiplied by the unit cost of 
an outpatient visit as determined in round two of 
the Delphi panel exercise.10 Figures were estimated 
for both adults and children.
To obtain an estimation of the number of 
emergency room (ER) visits and total inpatient 
treatment costs, the percentage of asthma sufferers 
visiting an ER as reported in the AIRGNE study was 
multiplied by the total number of asthma patients 
treated in government healthcare facilities. The 
result was then multiplied by the average number of 
ER visits per year as reported in the AIRGNE study 
and the Asthma Control in Oman study to obtain 
the total number of ER visits per year.12,14 The unit 
cost of an ER visit as determined in round two of 
the Delphi exercise was used to obtain the total cost 
of ER visits. Costs were estimated for both adults 
and children. 
The total inpatient treatment cost estimate was 
calculated in a similar manner using estimates from 
round two of the Delphi exercise. To obtain an 
estimation of total direct treatment cost, the total 
direct costs for adults and children were estimated 
to be the sum of costs for outpatient and inpatient 
care, ER visits, and the costs of asthma medications. 
All data were obtained from the MOH Purchasing 
Department. A sensitivity analysis, according to the 
results from the Delphi panel, was conducted based 
on the lowest 50% of the values collected in round 
one.
Results
The best estimates of asthma prevalence in Oman 
obtained from the Delphi panel were 7.3% of adults 
and 12.7% of children, which corresponded to a total 
of 91,646 adults and 55,426 children, respectively. 
Table 1: Statistics on Omani nationals suffering from 
asthma and using Ministry of Health facilities
Adults (16+) Children (5+)
Population 2009 1,321,501 459,398 
Asthma prevalence 7.3% 12.7%










Table 2: Calculations leading to total cost of inpatient 
treatments of asthma for Omani nationals in Omani 
riyals
Adults (16+) Children (5+) 






Number of sufferers 
hospitalised
24,744 23,279 




hospitalised per patient 
per year
2.6 3.9
total hospital nights 
per year
270,209 217,892 
Cost of an overnight 
stay in oMr
67 73
Cost of inpatient visits 
in oMr
18,104,026 15,906,126
MOH = Ministry of Health; OMR = Omani riyals.
Table 3: Calculations leading to the total cost of 
emergency room visits by Omani nationals due to 
asthma in Omani riyals
Adults (16+) Children (5+)
total number of asthma 
sufferers using MoH
91,646 55,426 
Percentage making an 
emergency visit in past 
year
58% 55%
total number of 
sufferers making Er 
visits
53,155 30,485 
Average number of 
visits per patient per 
year
3.8 6.3
total number of visits 
per year
201,988 192,052 
Unit cost of an 
emergency visit 
39 39
total cost of emergency 
visits in oMr
7,877,532 7,490,042 
MOH = Ministry of Health; ER = emergency room; OMR = Omani 
riyals.
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Of these, 95% adults and the percentage of children 
were estimated to be using government healthcare 
facilities [Table 1]. 
Inpatient visits accounted for the largest portion 
of total direct costs for asthma treatment. The 
total number of nights that adult asthma patients 
spent in hospital per year was estimated to be 
270,209, incurring a total cost of OMR 18,104,026. 
The corresponding numbers for children were 
estimated to be 217,892 nights, at a total cost of 
OMR 15,906,126 [Table 2].
The second largest component of total direct 
costs was the cost of ER visits at 25%. The total 
estimated number of ER visits per year for adults 
with asthma was 53,155 at a total cost of OMR 
7,877,532. For children, the total number of ER 
visits per year was 30,485 at a total cost of OMR 
7,490,042 [Table 3]. There were 318,928 outpatient 
visits per year estimated for adults with asthma 
and 139,176 for children. The total cost of 
outpatient visits for adults was OMR 8,292,139 and 
for children, OMR 3,618,566, making up 20% of the 
total cost of asthma treatment [Table 4].
The overall cost of asthma treatment is shown 
in Table 5. The subtotal (before including the cost 
of medicines) for treatment visits for adults and 
children was OMR 61,288,431. Added together 
with the cost of medicine, the total direct cost of 
asthma treatment was over OMR 61 million (OMR 
418 per patient).
Although the costs changed when using the 
lowest 50% of the values collected in round one of 
the Delphi exercise, the inpatient and ER treatment 
costs still made up the largest portion of the total 
direct costs, while the cost of medications was 
substantially smaller. 
Discussion
To our knowledge, the present study is the first to 
evaluate the cost burden of asthma in Oman. We 
found that asthma treatment causes a substantial 
financial burden on the healthcare system with 
results showing that the direct cost of asthma 
treatment is estimated to be OMR 61,500,293/
USD 159,900,762. This cost was primarily driven 
by inpatient stays and ER visits, which made up 
approximately 80% of direct costs. Compared to 
these costs, the cost of medications is minimal, 
less than 1% of the total direct costs. It should 
be noted that these estimates comprise only the 
costs incurred by Omani nationals in government 
healthcare facilities, and do not include the private 
sector or the treatment of expatriates, the majority 
of whom are followed up in the private sector.
This high proportion of costs is further 
emphasised when noting that the number of ER 
visits and hospitalisations for asthma patients in 
Oman are considerably higher than in Europe. The 
AIRGNE study reported that 21% of adults and 
children with asthma in Oman reported visiting an 
ER in the year preceding the study.14 In contrast, 
only 10% of asthma sufferers in Europe reported 
Table 4: Calculations leading to the total cost of 
outpatient visits by Omani nationals (Omani riyals)
 Adults (16+) Children (5+)







Asthma sufferers who 
are MoH patients 
79,732 44,895 
outpatient visits 
per patient per year 
(AIrGNE)
4.0 3.1
total number of 
outpatient visits per 
year
318,928 139,176 
Unit cost of an 
outpatient visit 
26 26
total cost of outpatient 
visits 
8,292,139 3,618,566
MOH = Ministry of Health; AIRGNE = Asthma Insights and Reality 
for the Gulf and Near East.
Table 5: Calculations leading to an estimate of the total 

















7,877,532 7,490,042 15,367,574 
Cost of 
inpatient stays
18,104,026 15,906,126 34,010,152 
total non-drug 
cost
34,273,696 27,014,735 61,288,431 
Cost of medicines 211,862 
Total direct cost of treatment 61,500,293
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visiting an ER in the year preceding the study, 
as reported in the Asthma Insights and Reality 
in Europe (AIRE) study.14 In addition, the AIRE 
study reported that only 7% of sufferers required 
overnight hospitalisation in Europe during the 
previous 12 months compared to 30% in Oman as 
reported in the AIRGNE study.15 Inpatient stays and 
ER visits are both correlated with a lower level of 
asthma control, leading to a potentially larger cost 
burden to the MOH.  
In contrast to the distribution of costs in 
Europe, of the EUR 7.9 billion in annual direct 
costs 48% (EUR 3.8 billion) was for outpatient care, 
46% (EUR 3.6 billion) was for drug costs and 6% 
(EUR 0.5 billion) for inpatient care.4 In the USA, 
it was reported that prescription medications and 
physician office visits accounted for the largest share 
of total expenditures and comprised approximately 
38% of the total incremental expenditures for 
asthma in children and approximately 49% among 
adults.5 Comparatively, the higher proportion of 
expenditures on outpatient visits, inpatient stays, 
and ER visits for asthma in Oman could reflect a 
different level of disease control to that of asthma 
patients in the USA and Europe. 
The strengths of this study include its novelty 
and the overall comprehensiveness of national 
Omani data. However, there are some limitations 
to our research. Asthma prevalence and unit cost 
estimates were based on results from an expert 
panel using the Delphi technique. Although the 
use of two rounds enhanced the reliability of the 
estimates, the results are still dependent on the 
individual opinions of the panel members which 
may result in the subjective estimation of costs and 
prevalence. 
Conclusion
The best method of controlling asthma is the regular 
use of controller medication and the education of 
patients, family, caregivers, school personnel, and so 
on. Given the high medical expenditures associated 
with ER and inpatient visits, and the relatively 
lower expenditure on medications in Oman, it 
is reasonable to expect that improving levels of 
asthma control would correspond to a positive 
impact on total MOH expenditure, even if this 
expenditure increases over time. Cost-saving efforts 
should therefore be focused on improving asthma 
control rather than on reducing expenditures on 
medication procurement.
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